ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer is kicking off the new year with a couple of new drug approvals. FDA has approved Exubera, an inhalable insulin for the treatment of diabetes. Last month, Pfizer agreed to pay Sanofi-Aventis $1.3 billion for the full rights to Exubera, which is the first alternative to insulin injections. Merrill Lynch estimates Exubera will bring in $1.1 billion in annual sales by 2010. Pfizer also gained approval for Sutent, a small molecule that inhibits multiple tyrosine kinases. In an unusual move, FDA approved Sutent for two oncology indications: advanced kidney cancer and a rare stomach cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter